Workflow
Defiance Silver Corp. Announces Closing of Brokered LIFE Offering and Concurrent Non-Brokered Offering for Total Gross Proceeds of C$16.5 Million
aTyr PharmaaTyr Pharma(US:LIFE) Newsfileยท2025-06-20 18:10

Core Viewpoint - Defiance Silver Corp. successfully closed a brokered private placement and a concurrent non-brokered offering, raising total gross proceeds of C$16.5 million [2]. Group 1: Brokered Offering - The brokered offering generated gross proceeds of C$15 million, with the sale of 60 million units at a price of C$0.25 per unit [2][3]. - Each unit consists of one common share and one-half of a common share purchase warrant, with each warrant allowing the purchase of one common share at C$0.35 until June 20, 2027 [3]. - Red Cloud Securities Inc. acted as the sole agent, receiving a cash commission of C$824,950 and 3,299,800 broker warrants [4]. Group 2: Use of Proceeds - The net proceeds from the brokered offering will be allocated for exploration work, a mineral resource estimate at the San Acacio project, cash option payments on the Tepal project, and general working capital [5]. Group 3: Non-Brokered Offering - The non-brokered offering raised additional gross proceeds of up to C$1.5 million by selling 6 million units at C$0.25 per unit [11]. - Each non-brokered unit also consists of one common share and one-half of a common share purchase warrant, with similar terms as the brokered offering [11]. - A cash commission of C$90,000 was paid to an arm-length finder, along with the issuance of 360,000 finder warrants [12]. Group 4: Regulatory Compliance - The units were issued under the listed issuer financing exemption and are freely tradeable under applicable Canadian securities legislation [6]. - The offerings are subject to final approval from the TSX Venture Exchange [13]. Group 5: Company Overview - Defiance Silver Corp. is focused on advancing the Zacatecas project and the Tepal Gold/Copper project in Mexico, aiming to develop premier silver and gold deposits [15].